Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Biodexa Pharmaceuticals ( (BDRX) ) has provided an announcement.
On February 13, 2025, Biodexa Pharmaceuticals PLC announced its participation in the Emerging Growth Conference, scheduled for February 19, 2025. The event will feature a live, interactive presentation by CEO/CFO Stephen Stamp, providing an opportunity for investors and stakeholders to engage with the company directly. This conference serves as a platform for Biodexa to communicate its strategic initiatives and innovative pipeline to a broad audience, potentially impacting its industry positioning and investor relations.
More about Biodexa Pharmaceuticals
Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative products for treating diseases with unmet medical needs. The company’s key development programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer indications. Biodexa utilizes proprietary drug delivery technologies to improve the bio-delivery and bio-distribution of medicines. The company is headquartered in Cardiff, UK.
YTD Price Performance: 17.36%
Average Trading Volume: 537,435
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.21M
Find detailed analytics on BDRX stock on TipRanks’ Stock Analysis page.
